Kadmon Holdings Inc (NYSE:KDMN)’s share price traded up 6.5% during mid-day trading on Tuesday . The company traded as high as $3.82 and last traded at $3.63. 1,240,700 shares were traded during mid-day trading, an increase of 49% from the average session volume of 830,447 shares. The stock had previously closed at $3.41.
Several equities research analysts have recently weighed in on the company. HC Wainwright set a $25.00 price objective on Kadmon and gave the company a “buy” rating in a report on Monday, August 13th. Zacks Investment Research raised Kadmon from a “hold” rating to a “buy” rating and set a $4.25 price objective for the company in a report on Wednesday, July 11th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $11.45.
The firm has a market cap of $410.56 million, a price-to-earnings ratio of -2.44 and a beta of 3.49.
Kadmon (NYSE:KDMN) last posted its quarterly earnings data on Thursday, August 9th. The company reported $0.24 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.26) by $0.50. The firm had revenue of $0.36 million during the quarter, compared to analyst estimates of $0.90 million. research analysts anticipate that Kadmon Holdings Inc will post -0.94 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Northern Trust Corp lifted its holdings in shares of Kadmon by 395.3% during the second quarter. Northern Trust Corp now owns 791,781 shares of the company’s stock worth $3,159,000 after purchasing an additional 631,914 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Kadmon by 191.4% during the second quarter. Bank of New York Mellon Corp now owns 198,063 shares of the company’s stock worth $790,000 after purchasing an additional 130,096 shares during the period. MetLife Investment Advisors LLC acquired a new stake in shares of Kadmon during the second quarter worth $148,000. Metropolitan Life Insurance Co. NY acquired a new stake in shares of Kadmon during the second quarter worth $105,000. Finally, Acuta Capital Partners LLC lifted its holdings in shares of Kadmon by 52.3% during the second quarter. Acuta Capital Partners LLC now owns 9,060,014 shares of the company’s stock worth $36,149,000 after purchasing an additional 3,110,014 shares during the period. 69.66% of the stock is owned by hedge funds and other institutional investors.
Kadmon Company Profile (NYSE:KDMN)
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.
Read More: What is the NASDAQ?
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.